Serotonergic Pharmacotherapy for Agitation of Dementia (SPAD)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Bruce Pollock, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00009204
First received: January 23, 2001
Last updated: June 18, 2013
Last verified: June 2013
  Purpose

This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.


Condition Intervention Phase
Dementia
Alzheimer Disease
Dementia, Vascular
Drug: Citalopram [Celexa]
Drug: Perphenazine [Trilafon]
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Serotonergic Pharmacotherapy for Agitation of Dementia

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Study Start Date: September 1995
Study Completion Date: April 2002
Primary Completion Date: April 2000 (Final data collection date for primary outcome measure)
Detailed Description:

The principal investigator is conducting an inpatient study at Western Psychiatric Institute and Clinic involving two medications for treatment of emotional and behavioral disturbances that may accompany dementia. In this study, 112 patients will be enrolled for up to 17 days in order to investigate the safety and effectiveness of both medications. Forty-two of these patients will be given a recently FDA-approved antidepressant medication called citalopram and 42 will receive one of our current, usual antipsychotic medications called perphenazine. An additional 28 patients will be given non-active placebo capsules. Which treatment a patient is given during the study will be determined by chance. Findings from this investigation may directly lead to the improvement of symptoms such as: agitation, hostility, suspiciousness, hallucinations, and unusual thoughts. Improved treatment of problematic behaviors and a decrease in medication-associated side effects would enable dementia patients to be cared for in their home environments for longer periods of time.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meets DSM-IV criteria for diagnosis of dementia of the Alzheimer's type (AD), Vascular dementia (VD), mixed (AD and VD) or dementia NOS (Not Otherwise Specified)
  • Presents with psychosis or behavioral problems severe enough to endanger the patient's health, well-being or safety, as evidenced by a score of at least 3 (moderate) on one of the Neurobehavioral Rating Scale (NBRS) agitation items (8,11,14) or psychosis items (16,18,20) and are not secondary to physical illness nor amenable to environmental optimization
  • Able to participate in study evaluations and ingest oral medication
  • Has next of kin or a guardian available to consent to patient's participation.

Exclusion Criteria:

  • Has an unstable medical illness including significant cardiac (specifically bradycardia with ventricular rate below 50), renal, hepatic, or neurological illness (especially Parkinson's disease) other than dementia
  • Meets DSM-IV criteria for Delirium upon admission to Western Psychiatric Institute and Clinic
  • Has been medicated within 4 weeks of protocol admission with fluoxetine or 2 weeks with a monoamine oxidase inhibitor (patients will undergo a monitored psychotropic drug washout prior to entering the protocol)
  • Is currently being treated with cognitive enhancing drugs (Tacrine or Aricept) or any experimental drug
  • Has a concurrent diagnosis of schizophrenia, bipolar disorder, or major depression
  • Has preexisting orthostatic hypotension (with > 20 mmHg change from sitting to standing pressure)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00009204

Locations
United States, Pennsylvania
University of Pittsburgh Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Bruce Pollock
Investigators
Principal Investigator: Bruce G. Pollock, M.D., Ph.D. Western Psychiatric Institute and Clinic
  More Information

No publications provided

Responsible Party: Bruce Pollock, Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00009204     History of Changes
Obsolete Identifiers: NCT00000184
Other Study ID Numbers: R01 MH59666-01, R01MH059666-01, IA0014, DSIR GT-GP
Study First Received: January 23, 2001
Last Updated: June 18, 2013
Health Authority: United States: Federal Government

Keywords provided by University of Pittsburgh:
Behavioral problems
Agitation

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Dementia, Vascular
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Cerebrovascular Disorders
Intracranial Arteriosclerosis
Intracranial Arterial Diseases
Leukoencephalopathies
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Dyskinesias
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Citalopram
Perphenazine
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents

ClinicalTrials.gov processed this record on April 17, 2014